Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK4424989
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK4424989 is an investigational **four-component prophylactic vaccine** developed by GSK to prevent infections caused by *Streptococcus pyogenes* (group A streptococcus, Strep A). The recombinant protein and glycoconjugate vaccine is designed to induce antibody responses against four Strep A antigens: streptolysin O, *S. pyogenes* cell envelope protease, *S. pyogenes* adhesion and division protein, and group A carbohydrate. It is being evaluated in a randomized, placebo-controlled Phase 1 study in healthy adults aged 18–25 years, using formulations adjuvanted with aluminum hydroxide or AS37.
- Other names
- GSK 4-component Strep A vaccineGSK4-component Strep A vaccineGSK-4-component Strep A vaccine4-component vaccine against Group A Streptococcus pyogenes
02
Targets
GAC (Group A carbohydrate antigen)SpyCEP (Streptococcus pyogenes cell envelope protease)SLO (Streptolysin O)SpyAD (Streptococcus pyogenes adhesion and division protein)
Beyond the preview
Go deeper on GSK4424989.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK4424989.